Key Companies Covered in the Respiratory Drugs Market Research Report Are AstraZeneca, Fibrogen Inc., Novartis AG, Abbott, GlaxoSmithKline plc, Pfizer Inc., F. Hoffmann-La Roche, Boehringer Ingelheim International GmbH, Merck & Co. Inc., Sunovion Pharmaceuticals Inc and other key market players.
New York, Jan. 12, 2021 (GLOBE NEWSWIRE) -- With availability of limited preventive or therapeutic interventions for respiratory viruses resulting in morbidity and mortality globally, there is significant increase in investments through authoritative bodies for research and development activities related to case studies, management, prevention and control of these viruses. For instance, as a global response to novel coronavirus (nCoV), numerous economies have formally signed for COVAX facility to speed up the development and unbiased accessibility to tests, treatment and vaccines for COVID-19. More than 185 countries have participated in this Gavi-coordinated facility to ensure the availability of vaccines in both higher- and middle-income countries. Moreover, UNICEF (United Nations International Children's Emergency Fund), one of the renowned social welfare organizations has procured 1 billion syringes and planned to deliver 2 billion doses of vaccine by the end of 2021, keeping social and frontline health care workers along with people at high risk at priority.
Research Nester added a detailed report on ‘Global Respiratory Drugs Market’ in its repository of market intelligence reports that include different market segments and their comprehensive evaluation. The report also covers detailed analysis covering growth drivers, challenges and opportunities along with pointers adopted by major players to stay ahead of their competitors.
In a fact sheet provided by the World Health Organization (W.H.O.), among the 10 leading causes for mortality amounting 55% of the 55.4 million deaths globally in 2019, the chronic obstructive pulmonary disease (COPD) ranked as the 3rd leading cause of death. Be it infectious or chronic, the respiratory disorders are among the leading causes of death and disability around the world. Some of the lung problems include asthma, COPD, cystic fibrosis, pneumonia, lung cancer, acute respiratory distress syndrome (ARDS), chronic and acute bronchitis, and lung cancer among other lung diseases. Sedentary lifestyle, diet, allergens, indoor and outdoor air pollutants and tobacco smoke are some of the major risk factors pertaining to the chronic respiratory diseases. For instance, in other statistics by W.H.O., tobacco is responsible for 8 million deaths on an annual basis, out of which, more than 7 million are caused by direct tobacco usage, whereas, about 1.2 million deaths are caused by second-hand smoke. On the back of these factors, the global respiratory drugs market is anticipated to witness significant growth and is estimated to expand at around 6% over the forecast period, i.e., 2019-2027. The market is projected to cross market value of USD 25,500 million by the end of 2027.
“The Final Report will cover the impact analysis of COVID-19 on this industry.”
Get a sample copy of the report@ https://www.researchnester.com/sample-request-2514
Globally, the respiratory drugs market is segmented on the basis of regions into North America, Europe, Latin America, Asia Pacific and Middle East and Africa. With 40% of the market share in 2019, the respiratory drugs market in North America held the highest stance in the overall market and is estimated to hold this position throughout the forecast period. This growth is closely followed by the market in Asia Pacific, that is estimated to touch USD 9000 Million by the end of 2027. Tobacco smoking (including both active and passive) and other indoor and outdoor air pollutants are among the major risk factors for chronic respiratory diseases. In 2018, China was the leading producer of tobacco (around 2 million metric tons), whereas, India ranked as the 3rd largest tobacco producing country around the world. According to W.H.O., tobacco accounts for 9.5% of all deaths (estimated 1 million) every year in India. These are some of the factors that are driving the growth of the market in this region.
However, there is high risk of failure and the time required to develop new medicine comprising discovery, trials, approvals for registration, and consumption is usually high. Moreover, stringent regulatory laws and requirement of high investment for research and development activities pertaining to respiratory drugs is estimated to act as barriers to the growth of the global respiratory drugs market.
The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).
Based on drugs, the respiratory drugs market is segmented into anti-asthmatics & COPD drugs, idiopathic pulmonary fibrosis drugs and others. Among these segments, the anti-asthmatics and COPD drugs segment is estimated to attain highest market value throughout the forecast period. Presently, there is no cure for asthma or COPD, however, these diseases can be treated where symptoms can be controlled with improved quality life. Chronic respiratory diseases are responsible for around 8% of all deaths in the United States. According to the analysis between the years 2013-2017, provided by Centers for Disease Control and Prevention (CDC), around 2.4 million among 106 million workers (non-smokers, mostly that are exposed to various kinds of lung irritants) were diagnosed with COPD, where higher prevalence was reported among workers aged ≥65 years. However, cigarette smoking is the leading cause of COPD and accounts for more than 4,80,000 deaths in the United States on an annual basis. Similarly, among adults aged 18 or above, around 19,223 (in thousands) had asthma in the United States as per the Summary Health Statistics: National Health Interview Survey, 2018. The highest number of cases were registered among people aged between 18-44 years, followed by people aged 45-64 years.
Buy this report and get instant access @ https://www.researchnester.com/payment/rep-id-2514
The global respiratory drugs market is also segmented on the basis of formulation, disease, administration, drug delivery, and distribution channel.
Global Respiratory Drugs Market, Segmentation By Formulation
Tablets & Capsules
Syrups & Solutions
Global Respiratory Drugs Market, Segmentation By Disease
Idiopathic Pulmonary Fibrosis
Global Respiratory Drugs Market, Segmentation By Administration
Global Respiratory Drugs Market, Segmentation By Drug Delivery
Global Respiratory Drugs Market, Segmentation By Distribution Channel
Do You Have Any Query Or Specific Requirement? Ask to Our Expert@ https://www.researchnester.com/ask-the-analyst/rep-id-2514
Some of the prominent industry leaders mentioned in our report that are associated with the global respiratory drugs market are AstraZeneca, FibroGen Inc., Novartis AG, Abbott, GlaxoSmithKline plc, Pfizer Inc., F. Hoffmann-La Roche, Boehringer Ingelheim International GmbH, Merck & Co. Inc. and Sunovion Pharmaceuticals Inc.
Explore Our Recent Related Reports:
Neuroblastoma Drugs Market Segmentation By Drug Type (Cisplatin, Etoposide, Topotecan, Doxorubicin and Others); By Mechanism Type (Antibiotics, Microtubule Inhibitors, Alkylating Agents and Others); By Treatment Type (Chemotherapy, Bone Marrow Transplantation, Retinoid Therapy, Immunotherapy and Surgery); By Diagnosis Type (Imaging Test, Physical Test, Bone Marrow Sample Testing & Others); By End Users (Hospitals, Speciality Clinics, Homecare) - Global Demand Analysis & Opportunity Outlook 2028
Narcolepsy Drugs Market Segmentation By Disease Type (Extreme Sleepiness, Cataplexia and Others); By Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate and Others); By End Users (Retail Pharmacies, Drug Stores, E-Commerce and Others) - Global Demand Analysis & Opportunity Outlook 2028
Migraine Treatment Drugs Market Segmentation By Type (Chronic and Episodic); By Treatment Type (Abortive Treatment and Preventive Treatment); By Route of Administration Type (Injectable, Nasal Sprays, Oral and Others); By End Users (Hospitals, Online Pharmacies, Retail Pharmacies and Others) - Global Demand Analysis & Opportunity Outlook 2028
Antiretroviral Drugs Market Segmentation By Drug Type (Protease, Integrase, Multi-class Combination, NRTIs, NNRTIs and Others) – Global Demand Analysis & Opportunity Outlook 2028
Bi-directional Tachycardia Drugs Market Segmentation By Product (Non-Selective, β1-Selective and α-Blockers); By Route of Administration (Tablet, Liquid and Injection) and By Distribution Channel (Hospitals, Clinics, Research Laboratories and Retail Pharmacies) – Global Demand Analysis & Opportunity Outlook 2028
About Research Nester
Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.
Contact for more Info:
U.S. Phone: +1 646 586 9123
U.K. Phone: +44 203 608 5919